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Abstract
Gynaecological malignancies are the most common cancers of women and they  contribute 
to the significant amount of mortality. Women in developing countries are diagnosed in 
late stages and hence radiation is the common modality of therapy. Radiation is required 
in managing 80–90% of women with carcinoma cervix, 60% of women with endome‐
trial cancer and 50% of women with carcinoma vulva. The stage of the disease is the 
most important factor in survival and counselling is essential to ensure complete ther‐
apy. Radiation is used as a primary therapy, adjuvant therapy, neo‐adjuvant therapy 
and as palliation. The techniques include external beam radiation and brachytherapy 
or the combination of both. The newer techniques include IMRT‐, IGRT‐ and PET‐CT‐
guided therapies. Side effects/complications occur as acute during therapy, subacute 
within 3 months and chronic after 6 months. Management of these side effects is essential 
for increasing compliance of the patient so as to achieve high cure rates. Management 
of recurrent disease is a challenge and requires multidisciplinary approach involving 
Gynaecological Oncologist, Radiation Oncologist and Surgical Oncologist.
Keywords: radiotherapy, counselling, gynaecological malignancies, side effects, 
survival rates
1. Introduction
Radiation therapy in gynaecological malignancies is an essential component in achieving cure as 
well as palliation. Radiotherapy is required up to 80–90% of women with carcinoma cervix, 60% 
of women with endometrial carcinoma, 50% of women with carcinoma vulva, all women with 
vaginal cancer and 5% of women with ovarian cancer. The aim of radiotherapy is to kill the tumour 
cells without damaging the neighbouring normal tissues. The side effects of radiation can be severe 
and need to be recognized early to be treated effectively. Counselling of women suffering from 
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gynaecological malignancies who receive radiation is of great importance as adherence to treat‐
ment is one of the factors that influences survival rates. The most important part is the selection 
and categorization of women for radiation. The aim of this chapter is to appraise the readers about 
the burden of the gynaecological malignancies in a tertiary‐care set up, counselling and selection 
criteria for radiation, methods of radiation and the side effects and the outcome.
1.1. Burden of gynaecological malignancies in tertiary care set up
Cancer is the first and foremost cause of death in developing countries and the second most 
common cause in developed countries. Genital tract malignancies are the most common can‐
cers in women and the most common site affected is cervix followed by ovary and Uterine 
corpus [1]. The incidence of carcinoma cervix is 9 per 100,000 in developed countries as against 
17.8 per 100,000 in developing countries. The mortality attributed to carcinoma cervix is 3.2 per 
100,000 in developed regions when compared to 9.8 per 100,000 women in developing regions 
[2]. The cancer registry of our hospital recorded carcinoma cervix to be occurring in 70%, ovar‐
ian cancer in 20%, endometrial cancer in 9% and other cancers in 1% of cases in women. In 
India, every year 122,844 women were reported to be diagnosed with carcinoma cervix and 
67,477 died of the disease and at present the trend of this malignancy is decreasing in incidence 
[3]. The incidence of carcinoma cervix has declined by 75% in developed countries [1].
2. Selection criteria for radiation
Staging of the malignant disease is the most important factor in determining therapy and while 
planning contraindications to radiation to be looked for and histopathological  examination 
report is mandatory.
Contraindications for radiation: (1) Severe acute sepsis or febrile illness, (2) severe cancer 
cachexia, (3) myocardial infarction and (4) unequivocal histopathological report. Though there 
are no absolute contraindications, radiation is not the preferred therapy for radio‐insensitive 
tumours like fibrosarcoma, leiomyosarcoma and melanoma.
Carcinoma cervix: The most common histopathological type is squamous cell carcinoma. The 
incidence of adenocarcinoma is on the rise contributing to as much as 25% [4]. In spite of the 
availability of screening tests in the modern era, as high as 85% are still presenting in late 
stage. Adherence to therapy is poor as it was reported that only 38.8% complete radiother‐
apy [5]. Pre‐therapy staging is based on clinical examination and imaging findings. Recently, 
imaging techniques are playing a great role in planning therapy even though traditionally 
staging is done by clinical examination.
Role of imaging in staging:
• The accuracy of CT in staging carcinoma cervix is 63–88%. The sensitivity and specificity of 
CT in detecting pelvic lymph node involvement is shown in (Table 1)
• MRI distinguishes early from advanced disease, thereby stratifying patients for surgery 
and chemoradiation.
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• MRI is used to assess cervical stromal invasion and extra‐uterine extension and for assess‐
ing proximal extension of cervical tumour in young women with early‐stage disease for the 
feasibility of fertility‐preserving surgery [6].
• PET has sensitivity of 75% and specificity of 96% for the detection of pelvic lymphade‐
nopathy and sensitivity of 100% and specificity of 99% for the detection of para‐aortic 
lymphadenopathy. Its use has been increased, combined with CT, in the detection of nodal 
disease for locally advanced disease (>IB) [3, 5]. For early stage disease, the sensitivity and 
specificity of PET CT were about 73% and 97%, respectively.
• Grigsby et al. compared CT and FDG‐PET scanning for lymph node staging in 101 patients 
with carcinoma of the cervix. CT detected enlarged pelvic lymph nodes and para‐aortic 
lymph nodes in 20 and 7 patients, respectively, whereas PET detected abnormal FDG up‐
take in pelvic lymph nodes in 67, in para‐aortic lymph nodes in 21 and in supraclavicular 
lymph nodes in 8. Based on para‐aortic lymph node status, the 2‐year progression‐free 
survival rate was 64% in CT‐negative and PET‐negative patients, 18% in CT‐negative and 
PET‐positive patients and 14% in CT‐positive and PET‐positive  patients [7].
Survival rates are shown in Table 2.
Radiotherapy is advocated in the following situations:
(1) All stages especially when the woman is not fit for surgery or refuses surgery
(2) Following radical hysterectomy with positive pelvic lymph nodes
(3) Stages IIB to IV B
(4) Fertility sparing surgery which revealed a focus of positive lymph nodal metastasis
(5) Advanced stage carcinoma cervix following termination of pregnancy
(6) Persistent or recurrent disease
2.1. Carcinoma endometrium/Uterine Corpus
Carcinoma endometrium is the most common cancer of the uterus and its incidence is 
increasing. The median age is 63 years and more than 90% belong to 50 years of age or more 
and 25% occur before pre‐menopause. More than 75% are diagnosed in Stage I as the most 
common symptom is abnormal or postmenopausal bleeding. Survival rates are more than 
75%. Adenocarcinoma is the most common type with good prognosis, but it is relatively 
radioresistant.
CT Sensitivity (%) Specificity (%)
Pelvic + para‐aortic lymph nodes 44 93
Para‐aortic lymph nodes 67 100
Table 1. Sensitivity and specificity of CT.
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HPE grading:
Gx = Grade cannot be assessed
Grade 1 = Tumour cells are well‐differentiated
Grade2 = Tumour cells are moderately differentiated
Grade 3 = Tumour cells are poorly differentiated
The histopathological types are as follows:
1. Endometroid adenocarcinoma (secretory, ciliated, papillary)
2. Adenocarcinoma with squamous differentiation
3. Adenoacanthoma (benign squamous component)
4. Adenosquamous carcinoma (malignant squamous component)
5. Papillary serous carcinoma
6. Clear cell adenocarcinoma
7. Carcinosarcoma/malignant mixed mullerian tumour
8. Uterine sarcomas
S. no. Stage (FIGO) TNM (AJCC) Survival rates (5‐year 
observed rates)
Stage 0 93%
1 Stage I A1 (T1a1, N0, M0 93%
2 Stage I A1 (T1a2, N0, M0)
3 Stage I B (T1b, N0, M0) 80%
4 Stage B 1 (T1b1, N0, M0)
5 Stagve I B2 (T1b2, N0, M0)
Stage II (T2, N0, M0) 63%
6 Stage II A (T2a, N0, M0)
7 Stage II A1 (T2a1, N0, M0)
8 Stage II A2 (T2a2, N0, M0)
9 Stage 2 B (T2b, N0, M0) 58%
Stage III (T3, N0, M0)
10 Stage III A (T3a, N0, M0 35%
11 Stage III B T3b, N0, M0; OR T1‐T3, 
N1, M0) Hydronephrosis
32%
Stage IV
12 Stage IV A (T4, N0, M0) 16%
13 Stage IV B (any T, any N, M1) 15%
Table 2. Staging grouping of carcinoma cervix.
Radiotherapy66
9. Mucinous tumours
10. Undifferentiated.
Staging of endometrial carcinoma with survival rates is shown in Table 3. Radiotherapy is 
also indicated in Stage I as per risk stratification.
TNM FIGO 
stages
Surgico‐pathological findings Endometrial 
adenocarcinoma;  
5‐year survival
Endometrial 
carcinosarcoma; 
5‐year survival
Tx Primary tumour cannot be assessed
T0 No evidence of primary tumour
Tis Carcinoma in situ (Pre‐invasive carcinoma)
T1 I Tumour confined to Corpus 88–75% 70%
T1 a IA Tumour limited to endometrium or Less than a half of 
endometrium is involved
T1 b IB Tumour invasion of half or more than half of 
myometrium
f
T2 II Tumour invades stroma of cervix and confined to 
uterus
69% 45%
T3 a III A Tumour involvement of serosa and/or adnexa (direct 
extension or metastasis)
58–47% 30%
T3 b III B Vaginal involvement or parametrial involvement 
(direct extension or metastasis)
III C Metastasis to pelvic and/or para‐aortic lymph nodes
III C1 Pelvic lymph node metastasis
III C2 Para‐aortic lymph node metastasis
IV Tumour invades bladder mucosa and/or bowel 
mucosa and/or distant metastasis
17–15% 15%
T4 IV A Bladder mucosa and Bowel mucosa are involved by 
tumour but no distant metastasis
Bullous oedema is not considered as involvement
IV B Distant metastasis; Lymph nodes, Lungs, bones
Upper abdomen omentum; liver
Note: T = denotes extent of the tumour; N = designates whether cancer has spread to the lymph nodes; M = denotes 
distant metastasis.
Nx = Spread to nearby lymph nodes cannot be assessed; N0 = no spread to nearby lymph nodes; N1 = spread to pelvic 
lymph nodes; N2 = spread to para‐aortic lymph nodes.
Lymph node involvement: Stage I A‐5%, Stage I B‐10%; Stage I C‐15%; Stage II‐20% and Stage III‐55%.
Distant spread: M0 = there is no spread to distant lymph nodes, organs and tissues; M1 = spread to distant lymph nodes, 
upper abdomen, omentum, other organs, liver, lung.
Table 3. TNM classification and FIGO staging [8].
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Stage I low risk includes Stage I A grade 1 and 2 endometroid adenocarcinoma without or with 
minimal myometrial invasion.
Stage I intermediate-risk group includes Stage I with grade 1 or 2 adenocarcinoma with >50% 
myometrial invasion or grade 3 adenocarcinoma with superficial invasion and with extensive 
lymphovascular involvement
High-risk endometrial cancer includes Stage II with deep cervical stromal involvement and 
Stage III and IV disease.
2.2. Picture of USG and gross specimen of endometrial carcinoma (Figure 1)
Vulval and vaginal cancer:
A. Vulval carcinoma: Most common after 65 years of age but recently the incidence of carci‐
noma vulva in the age group between 40 and 49 years is reported to have been doubled. 
Its incidence is 1.3/100,000 women. Pathological types: Squamous cell carcinoma—90%; 
others include malignant melanoma, Paget's disease, Bartholin gland tumours, adenocarci‐
noma and basal cell carcinoma. Local recurrence is common when there is lymphovascular 
involvement, when the growth is of infiltrative type and when prominent fibromyxoid 
tumour is present at the edge of resected margins [9]. Gross picture of carcinoma vulva is 
shown in Figure 2.
Primary modality of therapy is surgical excision and groin lymph node dissection. Survival 
rates with staging are shown in Table 4.
Selection criteria for radiation:
Primary radiotherapy is suggested in women:
• When optimal surgical therapy is not possible.
• When Ulcerated groin nodes. Radiotherapy is followed by surgery or surgery followed 
by radiotherapy. However, surgery following radiation is associated with high morbidity.
Adjuvant radiotherapy is advised to groin and pelvic nodes in the following situations
Figure 1. (A) USG (TVS) picture of endometrial carcinoma showing increased endometrial thickness and increased 
vascularity and (B) picture of same uterus (panel A) as gross specimen showing endometrial carcinoma in the cavity.
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(1) When one or two nodes show the spread either microscopic or extra capsular.
(2) When the resected margins are involved.
Pre-operative radiotherapy is advocated to preserve anal sphincter function when the tumour is 
close to the anal sphincter. Radiotherapy may also be combined with chemotherapy. Chemo‐
RT may increase the morbidity, especially skin toxicity.
Recurrence is very common in vulvar cancer and it varies from 15 to 33%. The sites of recur‐
rence can be vulva itself (69.5%), groin nodes (24.3%) and distant sites (18.5%).
Stage grouping Explanation Survival rates (%)
Stage 0 (Tis,N0, M0) Carcinoma in situ(only vaginal epithelium is involved) 84
Stage I (T1, N0, M0) Cancer‐confined vagina; no spread to lymph nodes/
distant sites
Stage II (T2, No,M0) Cancer invades the connective tissue below vagina
No spread to lymph nodes and distant sites
 Stage III (T3, N0/1,M0)  
or (T1,/T2,N1, M0)
Spread of cancer to pelvic wall but not to lymph nodes 
or distant sites
Or spread to lateral pelvic wall and/to lymph nodes 
pelvic or inguinal
Not spread to distant sites
75
Stage IVA (T4, N0/N1,M0) Cancer spread to rectum/bladder
Lymph nodes may or may not have been involved
No distant metastasis
57
Stage IV B (Any T, Any N, M1) Cancer involves pelvic organs and spread to distant 
sites like lungs and liver, bone, etc.
Note: Five‐year survival rates for all stages together are reported as 50%; for squamous cell carcinoma 50%;for 
adenocarcinoma 60% and malignant melanoma 30%.
Table 4. FIGO and AJCC stage grouping and survival; carcinoma vulva.
Figure 2. Cauliflower type of growth on the vulva.
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B Vaginal carcinoma: Vaginal cancer is rarely encountered and its incidence is reported to 
be 1 in 11,000 and ocxcurs in women more than 70 years of age and only 15% occur in 
women less than 40 years. Presenting symptoms are usually abnormal discharge, bleeding 
per vaginum, post‐coital bleeding and mass per vaginum. Symptoms during late stages 
include constipation, pelvic pain and difficulty in micturition. Confirmation of  diagnosis is 
by speculum examination demonstrating a cervix free of disease and growth in the vagina. 
Biopsy determines the type of cancer. If the growth involves cervix and vagina, it is classi‐
fied under cervical cancer. If it involves vagina and vulva, it is classified as vulvar cancer. 
The most common pathological type is squamous cell carcinoma (70%); and others include 
adenocarcinoma (15%), melanoma (9%), sarcoma (4%) and miscellaneous [10].
3. Counselling for radiation
Counselling prior to radiotherapy is of utmost importance because of three reasons:
(1) To make the patient understand the process through which she would be going, i.e. the 
technique, the duration of therapy and the possible side effects and their significance and 
management.
(2) To make her compliant and complete the therapy for curative purposes or palliative pur‐
poses and follow‐up for further therapy like surgery or chemotherapy and also the pos‐
sibility or chances of recurrence.
(3) To help the patient to make informed decision and consent for the process.
Informed consent: [11]
Informed consent is to be taken by the radiotherapy counsellor/radiotherapy physician and 
it should include the diagnosis and stage of the disease, name of the procedure or treat‐
ment like external radiotherapy or brachytherapy or radio‐isotope treatment, site of the 
body where radiation would be delivered and Whether the procedure is done under seda‐
tion, local/regional/general anaesthesia. The duration of therapy and the proposed sessions 
of therapy and whether it is for curative purpose or for palliative purpose is to be stated and 
signed by the concerned health professional involved in the care of the woman. The most 
common acute side effects and late side effects should be mentioned in the document signed 
by the health professional. An information leaflet to the patient in the language known to her 
or relatives would be desirable and is of great benefit.
The second part of the consent form should include statement that the patient has understood 
the benefits of the therapy, the short‐term and long‐term side effects that can occur and has the 
opportunity to ask questions and read the management protocol. The statement should also 
include the liberty of the patient to ask to stop the treatment at any time during the therapy 
after understanding the consequences of the same. A  separate statement to be obtained from 
the reproductive aged women that she is not pregnant at this time of initiating the therapy 
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and would not plan to become pregnant during the course of therapy and she would inform 
the treating physician in case of such occurrence.
A statement for storing the data of the patient and its usage for the future purpose like research 
also can be included in this consent form.
Written consent would be obtained once prior to the procedure and at each session of treat‐
ment a verbal consent would be taken and this statement also to be included in the written 
consent form and to be signed and dated by the individual concerned.
In case of mental disease incapacitating the patient, a responsible attendant should be involved 
in the counselling process and in consenting in a similar way.
3.1. Survival rates
It is important to appraise the women and the relatives regarding prognosis and survival 
in addition to side effects whenever therapy is instituted. Though survival depends on 
many factors like age at the development of the malignancy, type of the tissue involved for 
example, cervix or endometrium or adnexa, histopathological type, modality of therapy, 
complications of therapy, compliance to therapy, associated co‐morbidities and the chance 
for recurrence, the most important factor is found to be the stage of the disease. In other 
words, spread of the cancerous tissue is the most important factor that is used to prognos‐
ticate and explain the modality of therapy and its outcomes like overall survival. Survival 
rates are expressed variously and the standard way is to express in terms of 5‐year survival. 
The survival rates for carcinoma cervix, endometrium and vulva are shown in Tables 2–4, 
respectively, and these should guide the clinician to explain the patient while undertaking 
counselling.
For carcinoma cervix, the survival rates reported in India include 47.7% in Mumbai‐based 
registry in North India and 38% in Bangalore‐based registry from South India. The 5‐year 
survival rate for recurrent disease is reported to be between 30–60% and the main modality of 
treatment for recurrence being surgery. The prognosis is better if the recurrence occurs after 6 
months of initial cure and the size of the recurrence is less than 3 cm [12].
4. Radiation therapy
Radiation therapy can be delivered as
(1) Primary radiotherapy
(2) Adjuvant radiotherapy
(3) Neoadjuvant radiotherapy
(4) Palliative radiotherapy
Radiation for Gynaecological Malignancies
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Primary radiotherapy: Primary radiotherapy involves the use of radiation therapy as the only 
modality of treatment either alone or in combination with chemotherapy which is used as 
a radiation sensitizer. Primary radiotherapy is used in the following situations: (1) women 
with unresectable, locally advanced disease; (2) women with resectable disease in whom the 
risk of surgical morbidity is unacceptably high and (3) women with medical risk factors that 
contraindicate primary surgical therapy.
Adjuvant radiotherapy: Early stage lesions of the lower genitourinary tract can be treated surgi‐
cally if resection can be accomplished with adequate negative margins and acceptable morbidity. 
Post‐operative radiotherapy/adjuvant radiotherapy is reserved for cases in which histopatho‐
logic analysis of the removed specimen reveals features suggesting a high risk of local recurrence.
Neoadjuvant radiotherapy: In advanced stage disease, sometimes neoadjuvant radiation is used 
before surgery to render an inoperable tumour operable and for preserving the organ.
Palliative radiotherapy: For women with distant metastatic disease at presentation, cure is 
unlikely and the aim of the treatment is to improve the quality of life. However, palliative 
radiotherapy is frequently used to palliate the symptoms of a painful bone metastasis, relieve 
features of raised intracranial tension in brain metastasis and relieve dyspnoea in superior 
vena cava obstruction.
4.1. Techniques of radiation
The two main modalities of irradiation are teletherapy (external beam radiation) and brachy‐
therapy. External beam irradiation is used to treat the whole pelvis including the uterus, 
cervix fallopian tubes and ovaries, parametria and the regional nodes. A linear accelerator is 
used to deliver mega voltage photons to treat the whole pelvis. Gamma rays from a cobalt‐60 
machine are also used to deliver radiation.
Brachytherapy: In this modality, source of radiation is placed inside the body as close to the 
tumour as possible. It usually consists of the placement of intrauterine and vaginal applica‐
tors. These are then loaded with the source of radiation. Cesium‐137 (137Cs) is the most popu‐
lar low‐dose rate (LDR) source and Iridium‐192 (192Ir) is the most common high‐dose rate 
source (HDR). Treatment with HDR is usually completed in a few minutes, whereas an LDR 
source takes 1 or 2 days to complete the treatment.
4.2. Technique of external beam radiation
External beam radiation in the treatment of carcinoma cervix aims at treating the whole pelvis. 
Whole pelvis involves treating the pelvic organs uterus, adnexa and upper third of vagina, 
parametrial tissues (cardinal, uterosacral and pubo‐cervical ligaments) and pelvic lymph 
nodes (internal and external iliac, obturator and pre‐sacral lymph nodes). Traditionally, the 
whole pelvis is treated with four fields—anterior‐posterior portals and two lateral fields 
(Figure 3A and B)]. Upper border is placed at L4‐L5 interspace to adequately cover the exter‐
nal iliac and lower common iliacs. The lower border is kept 3 cm below the lower extent of 
the tumour or lower border of obturator foramen if the vagina is not involved by the tumour. 
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The lateral borders are kept 2 cm lateral to the pelvic brim in order to adequately cover the 
iliac nodes. The upper and lower borders of the lateral fields correspond with those of the 
AP‐PA fields. The anterior border is kept at the anterior border of the pubic symphysis and 
the posterior border is placed to cover the entire sacrum. High‐energy beams of the range of 
6–15MV are used to deliver radiation. Dose of external beam radiation is 46 Gy in 23 fractions, 
200 cGy per fraction and one fraction a day 5 days a week. The dose distribution of four field 
box plan is shown in Figure 4A and bladder and rectum contours are shown in Figure 4B.
4.3. 3D planning techniques
• CT scan is taken with patient supine with arms on the chest, knees and lower legs immo‐
bilized, and anterior and lateral tattoos marked with radio‐opaque material aligned with 
lasers to prevent lateral rotation.
• Clinical examination is made in the treatment position and inferior extent of tumour in the 
vagina marked with radio‐opaque material.
• Patients will be instructed to maintain a constant bladder filling—‘comfortably full’—and in‐
structions will be given to empty the bladder two hours before simulation and to drink one litre 
of water mixed with 60 ml of Gastrovideo oral contrast. Ondansetron 8 mg or domperidone 10 
mg will be given if needed. To delineate large bowel, instructions will be given to drink one litre 
Figure 3. (A) Anterior field borders, (B) lateral field borders, and (C) HDR brachytherapy dose distribution [pear‐shaped].
Figure 4. (A) 3DCRT plan showing 95% coverage with four fields and (B) dose distribution of four field box plan 
showing 95% coverage with bladder and rectal contours.
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of water mixed with 60 ml of Gastrovideo oral contrast within 1 hour, 24 hours prior to simula‐
tion. Only liquid diet will be allowed after that, till simulation. Domperidone 10 mg will be given.
• CT Scan is taken from the first lumbar vertebra to 5 cm beyond the vaginal introitus. Intra‐
venous contrast is used to outline pelvic blood vessels to be used as surrogates for pelvic 
nodes in CTV delineation.
• Target volume definition
While defining clinical target volume (CTV), gross tumour volume (GTV) 
along with cervix, uterine volume is added. Entire uterus is delineated in‐
cluding the fundus. CTV‐T includes the primary GTV‐T with potential mi‐
croscopic spread to cervix, uterus, parametrial tissues, upper vagina, and 
broad and proximal utero‐sacral ligaments. If posterior extension of cervical 
tumour is present, the entire utero‐sacral ligaments and upper pre‐sacral 
nodes are included. CTV‐N includes the pelvic lymph nodes, i.e. obturator, 
internal, external and common iliac, and upper pre‐sacral nodes. These are 
delineated by identifying contrast‐enhanced pelvic blood vessels on each 
CT scan and using a 7 mm margin to create a 3D CTV.A typical CTV to 
PTV margin of 10 mm is used around the CTV‐T to allow for organ mo‐
tion of cervix and uterus and measured set‐up uncertainties. For CTV‐N, 
organ  motion occurs to a lesser extent and a 7–10 mm CTV to PTV margin is 
typically sufficient for set‐up variations. The contours of GTV, bladder and 
rectum are shown in (Figure 5).
Figure 5. Planning CT showing contours of GTV, bladder and rectum.
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4.4. Technique of brachytherapy
The high tolerance of the uterus and vagina make it ideally suited for brachytherapy. In 
brachytherapy, sealed radioactive sources are used to deliver radiation at short distances. 
It is possible to deliver a high dose locally to the tumour with a rapid dose fall‐off from the 
surrounding normal tissues. The commonly used isotope for high‐dose rate brachytherapy 
includes Iridium 192 and Cobalt 60. Caesium 137 is used for low‐dose rate brachytherapy. 
Uterine tandem is inserted into the length of which depends on the length of the uterus. 
Two ovoids are placed in the fornices and the vagina is packed with gauze. This decreases 
the dose to the rectum and bladder. Using an after loading technique, the source is intro‐
duced into the ovoids and tandem. The dwell time and dwell position is calculated so that 
the desired dose to Point A is achieved. In JIPMER, the dose prescribed to Point A is 8.5 Gy 
× 3 using Iridium 192. The classical isodose for intra‐cavitary brachytherapy of carcinoma 
cervix is pear‐shaped (Figure 3C).
4.5. JIPMER radiotherapy protocol for carcinoma cervix—summary (Table 5)
The standard treatment for women with FIGO IB2, IIA, IIB, IIIA, IIIB and IVA disease is 
concurrent chemo‐radiation. Surgery is not preferred because of the increased risk of posi‐
tive margins and positive nodes. Concurrent chemo‐radiotherapy is preferred to radiation 
alone since the addition of concurrent chemotherapy confers an overall survival advantage 
[RR risk reduction is 29%] [13]. Platinum‐based chemotherapy is preferred over non‐plati‐
num‐based chemotherapy since there is more benefit with platinum‐based compounds 
(5FU). The hazard ratio (HR) for platinum is 0.70 (95% confidence interval, CI 0.61–0.80; 
p< 0.0001) compared to 0.81 (95% CI 0.56–1.16; p=0.20) for non‐platinum‐based chemo‐
therapy. 118 chemoradiation with cisplatin alone is comparable to chemo‐radiation with 
cisplatin/5‐fluorouracil. However, concurrent chemo‐radiation for treatment of cervical 
cancer is associated with increased acute toxicities specifically haematological and gastro‐
intestinal toxicity [13].
4.6. RT for carcinoma cervix in special situations
(1) Acute haemorrhage
Women presenting with acute episode of hemorrhage need to be hospitalised and stabilised 
with blood transfusion and vaginal packing
Broad spectrum antibiotics and antifibrinolytics are to be started.
Haemostatic RT—Whole Pelvis EBRT‐2 Gy/# standard fractionation as per stage‐wise treat‐
ment protocol. If bleeding persists, brachytherapy with ovoids will be considered.
(2) Pregnancy: First and second trimester pregnant women are managed by medical termi‐
nation of pregnancy as appropriate for gestational age by medical methods .This is fol‐
lowed by stage‐wise treatment after 2 weeks
Radiation for Gynaecological Malignancies
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Third trimester—Pregnancy is continued till 34 weeks with fetal monitoring and institution of 
steroids for fetal lung maturity followed by elective caesarean section. Stage‐wise treatment is 
undertaken after 4 to 6 weeks of caesarean section.
(3) Utero‐vaginal prolapse: Manual reduction during RT if possible; procedentia—prolapse 
reduction under anaesthesia and labial stitching followed by RT.
(4) HIV:HAART—Highly active anti‐retroviral treatment
CD4 > 200 cells/ml—Stage‐wise treatment with  
radiotherapy + chemotherapy
CD4 50–200 cells/ml—Stage‐wise treatment with radiotherapy
CD4 < 50 cells/ml—palliation of symptoms
Use of universal aseptic precautions during P/V examination.
Stage EBRT ICBT‐HDR BED LQED at 
2 Gy/#
Recommended 
dose to  
point A
IA1 0 7 Gy× 6#
Ovoid &tandem
71.4 59.5 70–80 Gy
IA2, IB1, IIA1,  
IB2, IIA2
46 Gy/23# WP 8.5 Gy× 3#
Ovoid &tandem or ring &tandem
102.4 85.3 80–85 Gy
IIB 45 Gy/20# WP
or
46 Gy/23# WP
8.5 Gy× 3#
Ring &tandem or ovoid &tandem
102.3
102.4
85.2
85.3
>85 Gy
IIIA 46 Gy/23# WP
4 Gy/2#PM boost
6 Gy/3# PO
6 Gy× 3# linear applicator 96 80 85–90 Gy
IIIB
<2/3 of upper 
vaginal
involvement
45 Gy/20# WP
4.5 Gy/2# PM‐Boost
Or
46 Gy/23# WP
4 Gy/2# PM‐Boost
8.5 Gy× 3#
Ring &tandem or
Ovoid &tandem
109.8
107.2
89.8
89.3
85–90 Gy
IIIB
>2/3 of upper 
vaginal
involvement
46 Gy/23# WP
4 Gy/2#PM boost
6 Gy/3# PO
6 Gy× 3# Linear applicator 96 80 85–90 Gy
IVA
(Poor performance 
status),
30–39 Gy/10–13#
(Palliative RT to 
gross disease)
No brachytherapy 39–50.7 32.5–
42.25
Post‐op 46 Gy/23# WP 8 Gy× 2#
Vault brachytherapy
84 70
Table 5. JIPMER radiotherapy protocol for carcinoma cervix—summary.
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4.7. Incidentally diagnosed carcinoma cervix after simple hysterectomy/Stump carcinoma 
after subtotal hysterectomy for benign disease
• Pathological review—no LVSI—Stage I A1— follow‐up
• Stage IA1 with LVSI (or) > Stage IA2 Negative margins, negative imaging—pelvic RT + 
brachytherapy + chemotherapy
(or)
Complete parametrectomy + upper vaginectomy + pelvic lymph node 
dissection + PA LN sampling followed by adjuvant RT or chemo RT as 
per the above indications
• Positive margins, gross residual disease—if imaging negative for nodal disease—chemo 
RT, if imaging positive for nodal disease—consider for surgical debulking of grossly en‐
larged nodes followed by chemo RT.
4.8. Carcinoma of the endometrium protocol at JIPMER
History and physical examination; biopsy report confirmation of carcinoma and type of carcinoma:
• Haemogram
• Kidney function tests—blood urea, serum creatinine, serum electrolytes, creatinine clearance
• Liver function tests
• Random blood sugar
• Chest X‐ray
• Ultrasonography—abdomen and pelvis
• HBs antigen
• HIV serology
• CECT/MRI abdomen and pelvis
• Cystoscopy and sigmoidoscopy as clinically indicated
4.9. The evidence present in treating endometrial cancer with radiotherapy
In women with Stage I intermediate‐risk external beam pelvic radiotherapy reduces the local 
as well as vaginal recurrences. Vaginal brachytherapy alone also can achieve  similar recur‐
rence rates in this group of women. In women with intermediate‐ to high‐risk group, the over‐
all survival is also similar with external pelvic beam radiation and vaginal  brachytherapy. 
The role of chemotherapy combined with radiation not well established.
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5. Evidence‐based recommendation ESMO‐ESGO‐ESTRO consensus [14] 
(Table 6)
5.1. Normal tissue tolerance
Organs at risk (OAR) in radiation therapy of endometrial cancer include the bladder, rectum, 
small intestine and the femoral heads.
Radiation therapy for endometrial cancer and tissue tolerance (Table 7).
EBRT for endometrial cancer: The technique almost similar as that of carcinoma cervix planning 
except that the AP/PA field upper border is placed at L5‐S1 junction. The pelvis is treated with 
EBRT to 45–50 Gy in 25–28 daily fractions using 6–18 MV photon beams. The target volume is 
defined by GTV of the entire uterus in inoperable cases. CTV includes vaginal cuff, obturator 
nodes, external, internal and common iliac nodes. Planning target volume (PTV) is calculated 
as CTV plus 0.5–1 cm or ITV (internal target volume) plus 0.5 cm.
Brachytherapy delivers high dose to the vagina while minimizing dose to organs at risk. A vagi‐
nal cylinder of largest feasible diameter is the most common applicator used. The radiation 
is delivered with low‐dose rate (LDR) or high‐dose rate (HDR) radiotherapy. 50–60 Gy is the 
LDR prescription to the surface over 60–70 h when used alone. When combined with EBRT, 
the prescription dose is reduced to 25–30 Gy. The HDR dose prescriptions recommended 
by the American Brachytherapy Society (ABS) for adjuvant endometrial cancer is as follows. 
Suggested doses of HDR alone (Table 8A) and suggested doses of HDR to be used with 45 Gy 
EBRT for adjuvant endometrial cancer (Table 8B).
5.2. Carcinoma of the vulva
In patients with early stage vulval cancer with high risk features, radiation is commonly 
delivered following surgery. In patients with locally advanced tumours, surgery will result 
in unacceptable morbidity and poor cosmetic outcome. Radiotherapy in combination with 
concurrent chemotherapy is used for ‘organ preservation’ and cure. Apart from biopsy confir‐
mation of vulval lesion, FNAC of clinically positive inguinal nodes is mandatory and all other 
investigations prior to RT as per other malignancies are undertaken.
Normal tissue tolerance: Organs at risk (OAR) in radiation therapy of vulvar cancer include the 
bladder, rectum, small intestine and the femoral head similar to that of endometrial cancer 
and the tolerance of vagina is <75–80 Gy.
5.3. RT planning techniques: simulation and field arrangements
• Photon energy of more than 6 MV is required for treatment. CT is required for measuring 
the depth of inguinal nodes. Patients are simulated with custom immobilizations. Supine, 
frog‐leg positions are preferred to reduce the bolus effect from skin folds, with full blad‐
ders to reduce dose to small bowel.
• Radio‐opaque markers should be used to delineate vulva tumour, scars, palpable lymph 
nodes, extent of vaginal involvement if present and anal verge.
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• Borders of AP field should include superiorly from mid‐sacroiliac joint to cover external 
and internal iliac nodes or L4‐L5 level to cover the common iliac nodes if internal or exter‐
nal iliac nodes appear suspicious or positive.
• Inferiorly it should include the entire vulva or lower margin of the tumour (whichever is 
more caudal).
• Lateral border should include greater trochanter to cover the inguinal nodes in the AP field 
and 2 cm beyond the outermost point of the pelvic inlet on the PA field.
• Narrow PA field: Superior and inferior extent to same as that of wide AP field but lateral 
extent is farther off from femur‐matching supplemental electron fields.
• Anterior electron fields to the lateral inguinal region matched with the exit PA field. Energy 
of the beam is selected depending on the CT depth of femoral vessels
• Conedown: After 45 Gy to the pelvis, fields have to be reduced to include the primary tumour and 
involved inguinal lymph nodes with 2–3 cm margin.
Risk group Description Recommended management
Low Stage I endometroid, grade 1–2, <50% 
myometrial invasion, LVSI negative
The risk of recurrence after surgery alone is less than 5%
No adjuvant treatment is recommended
Intermediate Stage I endometroid, grade 1–2, >50% 
myometrial invasion, LVSI negative
Vaginal brachytherapy
(PORTEC‐2)
High‐
intermediate
Stage I endometroid, grade 3, <50% 
myometrial invasion, regardless of 
LVSI status
Stage I endometroid, grade 1–2, LVSI 
unequivocally positive, regardless of 
depth of invasion
Node negative‐brachytherapy
No surgical nodal staging:
Adjuvant EBRT recommended for LVSI unequivocally 
positive to decrease pelvic recurrence
Adjuvant brachytherapy alone is recommended for grade 3 
and LVSI negative to decrease vaginal recurrence
High Stage I endometroid, grade 3, >50% 
myometrial invasion, regardless of 
LVSI status
Surgical nodal staging performed, node negative:
Adjuvant EBRT with limited fields should be considered to 
decrease locoregional recurrence
Adjuvant brachytherapy may be considered as an alternative
Adjuvant systemic therapy is under investigation
No surgical nodal staging:
Adjuvant EBRT is recommended for pelvic control and relapse 
free survival
Sequential adjuvant chemotherapy may be considered to 
improve PFS and CSS
There is more evidence to support giving chemotherapy and 
EBRT in combination rather than either treatment modality alone
High Stage II Surgical nodal staging performed, node negative:
Grade 1–2, LVSI negative: recommend vaginal brachytherapy 
to improve local control
Grade 3 or LVSI unequivocally positive:
Recommend limited field EBRT
Consider brachytherapy boost
Chemotherapy is under investigation
No surgical nodal staging:
EBRT is recommended
Consider brachytherapy boost
Grade 3 or LVSI unequivocally positive: sequential adjuvant 
chemotherapy should be considered
Radiation for Gynaecological Malignancies
http://dx.doi.org/10.5772/67202
79
5.4. Intensity‐modulated radiation therapy
Intensity‐modulated radiation therapy (IMRT) improves conformality and eliminates matching 
problem between electrons and photons over 3DCRT (3D conformal radiation) for vulvar cancer. 
OAR Dose limitations
Bladder V80 < 15%, V75 < 25%, V65 < 50%
Rectum V50 < 50%, V60 < 35%, V65 < 25%, V75 <15%
Small intestine V15 <120 cc, V45 < 195 cc
Femoral heads Dmax < 40 Gy
Note: V = volume of tissue receiving n% of Gy.
Table 7. Radiation therapy for endometrial cancer and tissue tolerance.
Number of HDR fractions Dose/fraction Dose‐specific point
3 7 0.5 cm depth
4 5.5 0.5 cm depth
5 4.7 0.5 cm depth
3 10.5 Vaginal surface
4 8.8 Vaginal surface
5 7.5 Vaginal surface
Table 8A. Suggested doses of HDR alone.
Risk group Description Recommended management
High Stage III endometroid, no residual 
disease
EBRT is recommended
IIIA: Chemotherapy and EBRT to be considered
IIIB: Chemotherapy and EBRT to be considered
IIIC1: Chemotherapy and EBRT to be considered
IIIC2: Chemotherapy and extended field EBRT to be considered
High Non‐endometroid (serous or clear 
cell or undifferentiated carcinoma or 
carcinosarcoma
Serous and clear cell after comprehensive staging:
Consider chemotherapy; clinical trials are encouraged
Stage IA, LVSI negative: Consider vaginal brachytherapy only 
without chemotherapy –
Stage ≥IB: EBRT may be considered in addition to 
chemotherapy, especially for node‐positive disease
Carcinosarcoma and undifferentiated tumours:
Chemotherapy is recommended
Consider EBRT; clinical trials are encouraged
Advanced Stage III residual disease, Stage IVA Palliative RT/Chemotherapy
Metastatic Stage IVB Palliative chemotherapy/RT/best supportive care
Note: The 5‐year risk of recurrence is 2–10, 20–25 and 30 % for low risk, intermediate risk and high risk, respectively [15].
Table 6. Evidence‐based recommendation ESMO‐ESGO‐ESTRO consensus [14].
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IMRT reduces the dose to bladder, rectum, small bowel and head of femur. Definitions of CTV 
and PTV in 3DCRT and IMRT are as follows: CTV should include 1‐cm margin including the 
entire vulvar region and the bilateral external iliac, internal iliac and inguinofemoral nodes. PTV 
should include 1 cm margin around CTV.
5.5. Dose prescriptions (Table 9)
Carcinoma of the vagina: Colposcopy‐directed biopsy of the cervix and vulva to rule out pri‐
mary cervical and/or vulvar cancer is undertaken apart from other investigations prior to 
radiotherapy. In women with early and locally advanced vaginal cancer, radiation is often the 
sole treatment either alone or in combination with concurrent chemotherapy which is used 
as a radiation sensitizer. RT comprising both external beam irradiation and brachytherapy is 
the treatment of choice. Brachytherapy can be intra‐cavitary or interstitial depending on the 
depth of invasion. Intra‐cavitary brachytherapy is used to treat superficial lesions <5mm in 
depth from the vaginal surface. Interstitial brachytherapy is used to treat lesions involving 
>5mm of depth from the vaginal surface.
5.6. Radiotherapy for vaginal cancer (Table 10)
5.6.1. RT planning techniques simulation and field arrangements
• Patients are simulated in supine, frog‐leg positions (to minimize the bolus effect from skin 
folds) with full bladders (to minimize the volume of small bowel in the radiation field), 
with custom immobilizations.
• CT scan will be taken from the first lumbar vertebra to 5 cm beyond the vaginal introitus, 
and anterior and lateral tattoos marked with radio‐opaque material aligned with lasers to 
prevent lateral rotation.
5.6.2. AP/PA field
Superior border will be placed at L5‐S1 and inferior border at 3–4 cm below the vaginal 
marker and lateral borders at 1.5–2cm of the true pelvic rim. If inguinal lymph nodes are to be 
treated, wide AP fields will be planned to cover inguinal regions with narrow posterior fields 
with 2:1 weighting.
Number of HDR fractions Dose/fraction Dose‐specific point
2 5.5 0.5 cm depth
3 4 0.5 cm depth
2 8 Vaginal surface
3 6 Vaginal surface
Table 8B. Suggested doses of HDR to be used with 45 Gy EBRT for adjuvant endometrial cancer.
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5.6.3. Dose prescriptions
EBRT dose of 46 Gy with brachytherapy dose of 25–30 Gy is recommended. EBRT boost to 
64–70 Gy is used instead of brachytherapy for extensive lesions and those involving recto‐
vaginal septum.
5.6.4. Normal tissue tolerance
Organs at risk (OAR) in radiation therapy of vaginal cancer include the bladder, rectum, small 
intestine and the femoral heads Table 11.
5.7. Carcinoma of the ovary
The role of radiation is limited in carcinoma ovary. Whole‐abdomen radiation has been used, 
but its popularity has waned because of the favourable toxicity profiles of the current chemo‐
therapeutic regimens.
6. Newer modalities
Newer external radiation techniques, such as intensity‐modulated radiation therapy (IMRT), 
image‐guided radiation therapy (IGRT), stereotactic body radiotherapy (SBRT), proton 
therapy and PET‐CT‐guided radiation, have been tried in gynaecological cancers, but these 
require further validation.
Stage Therapy
Stage I Brachytherapy alone or combined with EBRT
Stage II EBRT to the primary and pelvic lymph nodes along with brachytherapy boost is 
recommended. If the parametria are involved, treatment should include parametrial boost
Stage III–IV A EBRT to the primary and pelvic lymph nodes along with parametrial boost and 
brachytherapy boost, with concurrent chemotherapy is recommended
Table 10. Radiotherapy for vaginal cancer.
Setting Scenario Dose (Gy)
Preoperative 45–50
Post‐operative Microscopic residual 50
Extracapsular extension or node positive 55–60
Gross residual 65–70
Definitive Concurrent chemoradiation 60–65
Table 9. Dose prescriptions.
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6.1. Intensity‐modulated radiation therapy (IMRT)
The technique of IMRT was developed using inverse planning. Intensity of the beam will be 
modulated spatially with the help of multileaf collimators. The advantage of IMRT lies in the 
reduction of amount of radiation dose received by small bowel and bone marrow. The use 
of IMRT is still under evaluation for intact cervix cases, but has been validated in the post‐
operative setting. Gandhi et al. reported the toxicities of pelvic radiotherapy in 44 patients, of 
which 22 received 3DCRT and 22 received IMRT. IMRT resulted in significant reduction of 
gastrointestinal toxicities with comparable clinical outcome. Patients who received IMRT had 
fewer grade 2 and grade 3 gastrointestinal toxicities as compared with 3DCRT [16]. Du et al. 
evaluated the dosimetry, efficacy and toxicity of IMRT in advanced cervical cancer. IMRT pro‐
vided better target dose conformity and better sparing of small bowel, bladder and rectum. 
They concluded that IMRT resulted in improved dose distributions with significantly lower 
toxicities with comparable clinical outcome [17]. The dose distribution of IMRT is shown in 
Figure 6.
Figure 6. Dose distribution of IMRT showing 95% coverage.
OAR Dose limitations
Bladder V45 < 35%
Rectum V30 < 60%
Small intestine V15 <120 cc, V45 < 195 cc
Femoral heads V30 < 15%
Note: Vn% = volume of tissue receiving n% of Gy.
Table 11. Tissue tolerance for vaginal RT.
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6.2. Image‐guided radiation therapy (IGRT)
The definition of IGRT, as given by the American College of Radiology and American Society 
of Radiation Oncology practice guidelines, is a procedure that refines the delivery of thera‐
peutic radiation by applying image‐based target relocalization to allow proper patient reposi‐
tioning for the purpose of ensuring accurate treatment and minimizing the volume of normal 
tissue exposed to ionizing radiation [18]. It is particularly useful in cases with a large mobile 
uterus as seen in young women and with a concern regarding the position of the uterus in the 
planned radiation field.
6.3. Stereotactic body radiotherapy (SBRT)
SBRT delivers radiation with large fraction sizes using highly conformal treatment tech‐
niques. In isolated para‐aortic node cases, it has been considered for a nodal boost. It should 
not be used as replacement for brachytherapy due to the significant increase in normal tissue 
doses with SBRT as compared with brachytherapy.
6.4. Proton therapy
The rationale for proton therapy lies in the improvement of therapeutic ratio by reducing the 
radiation dose to non‐targeted tissues, thereby reducing toxicity and facilitating dose escala‐
tion to achieve increased tumour control. Proton therapy can offer the best way of sparing 
the small bowel and rectum and can contribute to significant decrease in acute and chronic 
toxicities in cervical cancer treatment.
6.5. Image‐guided brachytherapy
Currently, image‐guided adaptive brachytherapy in gynaecological malignancies is based 
on CT and MRI. Ultrasonography (USG) as an imaging modality for guidance is also being 
explored. Advantages of USG include easier availability, cost‐effectiveness and small learning 
curve which makes it highly useful in developing countries. Limited availability and acces‐
sibility to CT and MRI prevented the early adoption of these promising techniques. Potter et 
al. reported the clinical outcome of 156 patients treated with image‐guided brachytherapy. 
Ninety‐seven percent of patients achieved complete remission with 3‐year overall local con‐
trol rates of 95%, 3‐year overall cancer‐specific survival rates of 74% and 3‐year overall sur‐
vival rates of 68%. They concluded that there is reduction in major morbidity and pelvic 
recurrence with the use of image‐guided brachytherapy [19].
Side effects of pelvic radiation:
Radiation‐induced side effects depend on the type of tissue, dosage and methods of deliv‐
ery of radiation, and the manifestations can be acute and chronic. Acute side effects usually 
occur during or within the first 3 months of completing radiation. These include fatigue, 
skin irritation or redness of the skin and loose bowel movements discomfort when urinating. 
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Chronic side effects occur 3 months after completion of radiation. It includes skin changes 
like thinning of skin, radiation enteritis which manifest as loose stools and bleeding per 
rectum, cystitis, vaginal stenosis and intestinal obstruction and perforation are other uncom‐
mon side effects. Common late toxicities include vaginal stenosis/shortening, dryness, 
fibrosis, telangiectasia, atrophy of skin. Fracture of femoral neck has been implicated with 
osteoporosis and smoking. Avascular necrosis of the femoral head, though extremely rare, 
may also occur. Infection, lymphocyst formation and lymphoedema have been associated 
with groin radiation. Psychosocial consequences which are related to sexual function and 
body image may occur. With 200 Gy, the rate of tissue necrosis is less than 1% for cervical 
tissue and vagina is more sensitive with a tolerance of 100–140 Gy, beyond which necrosis is 
common. The complication of vesicovaginal fistula may result beyond a threshold of 150 Gy 
and rectovaginal fistula at 80 Gy [5].
Nutrition is important and should contain high protein. Plenty of oral fluids intake of 
more than 3 litre is necessary to avoid dehydration. When EBRT is employed, skin is the 
most commonly affected tissue. Avoiding soap and other irritants is important to avoid 
ulceration.
7. Follow‐up and management of side effects
• Two months for the first year, 3 months for the next 2 years, 6 months for the next 2 years 
and then annually from 5 years.
• History of side effects and physical examination including pelvic and rectal examination 
and biopsy if recurrent growth.
• CT/MRI for all patients during the first year of follow‐up. If cervix cannot be assessed, im‐
aging will be done annually.
• Patient education regarding sexual health, vaginal dilator use, vaginal lubricants/moistur‐
izers (oestrogen creams) is undertaken at each follow‐up visit.
• Patients with fistula, who had complete response on follow‐up, will be referred for fistula 
repair.
8. Treatment of recurrent carcinoma of cervix
• After previous surgery
Approximately 50% of patients with localized recurrences after surgery alone may be sal‐
vaged with radiation. EBRT (45–50 Gy) with concurrent chemotherapy followed by brachy‐
therapy is recommended. If the tumour is inaccessible for brachytherapy, dose escalation 
with IMRT with at least 65–70 Gy may be attempted.
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• After definitive irradiation
Important factors to be considered for re‐irradiation are the time period between the two 
treatments, beam energy, volume and doses delivered in the initial treatment. EBRT for recur‐
rent tumour is given to limited volumes (40–45 Gy, 1.8 Gy/fraction).
8.1. Treatment of recurrent carcinoma of endometrium
Radiation therapy can be used to treat small vaginal recurrences in patients who have not 
received prior radiation. EBRT (45–50 Gy) and brachytherapy are often combined.
8.2. Treatment of recurrent carcinoma of vagina
Lesions that recur after limited surgical procedures can be treated using radiation or more 
extensive surgery. Most patients have received prior EBRT and, thus, have options limited to 
surgery.
8.3. Treatment of recurrent carcinoma of vulva
If there is clinical local recurrence confined to vulva or clinical nodal recurrence, no prior RT, 
then EBRT with concurrent chemotherapy can be delivered. Doses range from 50.4 Gy in 1.8 
Gy/# for adjuvant therapy to 59.4–64.8 Gy in 1.8 Gy/# for unresectable disease. Large nodes 
may be boosted to a dose of 70 Gy.
9. Conclusion
Radiation therapy in gynaecological malignancies involves multidisciplinary approach, care‐
ful planning and execution. Counselling is an essential part to increase compliance and to 
achieve high cure rates.
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